Skip to main content

Table 2 First-trimester exposure to oseltamivir and congenital malformations among live or stillbirths

From: Oseltamivir in pregnancy and birth outcomes

Outcome Unexposed
N = 670,602
Exposed
N = 406
Crude odds ratio (95% CI) Adjusted odds ratio (95% CI)
Conventional regression analysisa Propensity-score matched regression analysisb
Any major congenital malformation 24,773 (3.7%) 19 (4.7%) 1.28 (0.81 to 2.03) 1.25 (0.78 to 2.01) 0.94 (0.49 to 1.83)
Congenital heart defects 4795 (0.7%) 8 (2.0%) 2.79 (1.39 to 5.62) 2.51 (1.19 to 5.31) 1.75 (0.51 to 5.98)
  1. CI confidence interval
  2. aAdjusted for age at conception, parity, smoking, marital status, obesity, prior delivery of a child with a malformation, respiratory diseases, any other chronic illness (cardiovascular disease, haematological disease, diabetes, neurological disease [including antidepressants or antiepileptics use], liver or kidney disease, rheumatic disease or inflammatory bowel disease) during the 12 months before conception
  3. bSample size: exposed = 397; unexposed = 397; prevalence of any major malformation, exposed/unexposed: 4.5%/4.8%; prevalence of congenital heart defects, exposed/unexposed: 1.8%/1.0%